Science Explorer Back to mapMap
Discussion
Company · New Brunswick · United States

SilaGene (United States)

silagene.comROR OpenAlex
Research works
3
▲ 279% vs 2018-21
Citations
28
8.8 per fractional work
Top-10% rate
0.0%
all institutions 10.0%
Open access
92%
world 40%
International
8%
world 18%
SilaGene (United States)

Not ranked overall: SilaGene (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does SilaGene (United States) work in?

In all years, 85% of research at SilaGene (United States) is in Life Sciences, 15% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (79%), Medicine (15%), Pharmacology, Toxicology and Pharmaceutics (6%). It does 1.7× the world's share of Life Sciences.

Life Sciences: 3 fractional works · 84.8% of its workBiochemistry, Genetics and Molecular Biology: 3 fractional works · 78.8% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 6.1% of its workHealth Sciences: 0 fractional works · 15.2% of its workMedicine: 0 fractional works · 15.2% of its workALL ITS WORKSilaGene (UnitedStates)3fractional works, all years
Life Sciences85%Health Sciences15%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 2 domains and 3 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology378.8%
    2. Pharmacology, Toxicology and Pharmaceutics06.1%
    1. Medicine015.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from SilaGene (United States)?

The most cited paper from SilaGene (United States) is "Small-Molecule-Targeting Hairpin Loop of hTERT Promoter G-Quadruplex Induces Cancer Cell Death" (Jin Hyang Song, Hyun-Jin Kang, Libia A. Luevano et al., 2019), with 58 citations. Next come "U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo" (7) and "Novel Brain-Penetrant, Small-Molecule Tubulin Destabilizers for the Treatment of Glioblastoma" (5).

Most cited papers
#PaperReleasedCitations
1 Small-Molecule-Targeting Hairpin Loop of hTERT Promoter G-Quadruplex Induces Cancer Cell Death Jin Hyang Song, Hyun-Jin Kang, Libia A. Luevano et al. · Cell chemical biology Open access 30 May 2019 58
2 U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo Rafal M. Goraczniak, B. Wall, Mark A. Behlke et al. · Molecular Therapy — Nucleic Acids Open access 2013 7
3 Novel Brain-Penetrant, Small-Molecule Tubulin Destabilizers for the Treatment of Glioblastoma Lilian A. Patrón, Helen Yeoman, Sydney Wilson et al. · Biomedicines Open access 9 Feb 2024 5
4 RGN6024 Is a Brain-Penetrant, Small-Molecule Tubulin Destabilizer for the Treatment of Glioblastoma Lilian A. Patrón, Helen Yeoman, Joseph Ramos et al. · Molecular Cancer Therapeutics 21 May 2025 2
5 Role of Human DNA Ligases in Mediating Pharmacological Activities of Flavonoids Daekyu Sun, Vijay M. Gokhale · International Journal of Molecular Sciences Open access 10 Feb 2025 1
All 8 most cited papers, with filters and sorting

Which research topics does SilaGene (United States) publish most on?

By volume in 2022-now: Microtubule and mitosis dynamics, Glioma Diagnosis and Treatment, Brain Metastases and Treatment and Cancer therapeutics and mechanisms.

Microtubule and mitosis dynamics: 0 fractional worksGlioma Diagnosis and Treatment: 0 fractional worksBrain Metastases and Treatment: 0 fractional worksCancer therapeutics and …0Cancer therapeutics and mechanisms: 0 fractional worksBioactive Compounds and …0Bioactive Compounds and Antitumor Agents: 0 fractional worksGenomics, phytochemicals, and oxidative stress: 0 fractional worksATP Synthase and ATPases Research: 0 fractional works
Cell BiologyGeneticsPulmonary and Respiratory MedicineMolecular Biology1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Microtubule and mitosis dynamics Cell Biology 0 works
  2. 2 Glioma Diagnosis and Treatment Genetics 0 works
  3. 3 Brain Metastases and Treatment Pulmonary and Respiratory Medicine 0 works
  4. 4 Cancer therapeutics and mechanisms Molecular Biology 0 works
  5. 5 Bioactive Compounds and Antitumor Agents Toxicology 0 works
  6. 6 Genomics, phytochemicals, and oxidative stress Molecular Biology 0 works
  7. 7 ATP Synthase and ATPases Research Molecular Biology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available92.2%not open7.8%

World: 40% of research is openly available.

with international co-authors7.8%domestic only92.2%

World: 18% is written across borders.

How has SilaGene (United States)'s research output changed?

Output in 2022-2025 was 279% higher than in 2018-2021.

still counting201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in New Brunswick

All research institutions in New Brunswick

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about SilaGene (United States). Posts are plain text and can be reported.